4.7 Article

Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality

Journal

RHEUMATOLOGY
Volume 58, Issue 4, Pages 636-644

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/key350

Keywords

scleroderma; systemic sclerosis; gastrointestinal manifestations; mortality; health-related quality of life

Categories

Funding

  1. Canadian Institutes of Health Research (CIHR) [FRN 83518]
  2. Scleroderma Society of Canada
  3. Scleroderma Society of Ontario
  4. Scleroderma Society of Saskatchewan
  5. Sclerodermie Quebec
  6. Cure Scleroderma Foundation
  7. INOVA Diagnostics Inc. (San Diego, CA, USA)
  8. Dr Fooke Laboratorien GmbH (Neuss, Germany)
  9. Euroimmun (Lubeck, Germany)
  10. Mikrogen GmbH (Neuried, Germany)
  11. Fonds de la recherche du Quebec - Sante (FRQS)
  12. Canadian Arthritis Network (CAN)
  13. Lady Davis Institute of Medical Research of the Jewish General Hospital, Montreal, QC
  14. Pfizer
  15. Actelion pharmaceuticals
  16. Scleroderma Australia
  17. Scleroderma Victoria
  18. Arthritis Australia
  19. Actelion Australia
  20. MOVE
  21. Australian Rheumatology Association
  22. Scleroderma Clinical Trials Consortium
  23. St Vincent's Hospital Research Endowment Fund
  24. Bayer
  25. CSL Biotherapies
  26. GlaxoSmithKline Australia
  27. Roche
  28. Hopital Maisonneuve Rosemont Department of Medicine Foundation Fund
  29. National Health and Medical Research Council of Australia Career Development Fellowship [APP 1126370]

Ask authors/readers for more resources

Objectives To examine the incidence, predictors and outcomes associated with severe gastrointestinal (GI) disease in a large inception SSc cohort. Methods SSc subjects with <2 years of disease duration were identified from two multicentre cohorts. Severe GI disease was defined as: malabsorption, hyperalimentation, pseudo-obstruction and/or 10% weight loss in association with the use of antibiotics for bacterial overgrowth or oesophageal stricture. Kaplan-Meier, multivariate logistic regression and Cox proportional hazard analyses were performed to determine the cumulative incidence rate, independent clinical correlates and mortality rate associated with severe GI disease. A longitudinal mixed model was used to assess the impact of severe GI disease on the Short Form Health Survey. Results In this inception SSc cohort, the probability of developing severe GI disease was estimated at 9.1% at 2 years and 16.0% at 4 years. In multivariate analysis, severe GI disease was associated with inflammatory myositis (odds ratio 4.68, 95% CI 1.65, 13.24), telangiectasias (odds ratio 2.45, 95% CI 1.19, 5.04) and modified Rodnan skin score (odds ratio 1.03, 95% CI 1.01, 1.07). Severe GI disease was associated with a >2-fold increase in the risk of death (hazard ratio 2.27, 95% CI 1.27, 4.09) and worse health-related quality of life [Short Form Health Survey physical ( = -2.37, P = 0.02) and mental ( = -2.86, P = 0.01) component summary scores]. Conclusion Severe GI disease is common in early SSc and is associated with significant morbidity and increased mortality. More research is needed to understand, prevent and mitigate severe GI disease in SSc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available